BIAF Stock Overview
Engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
bioAffinity Technologies, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.00 |
52 Week High | US$3.62 |
52 Week Low | US$0.95 |
Beta | 0 |
1 Month Change | 6.38% |
3 Month Change | 5.26% |
1 Year Change | 11.73% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -75.90% |
Recent News & Updates
Shareholder Returns
BIAF | US Biotechs | US Market | |
---|---|---|---|
7D | -13.0% | 0.02% | 1.2% |
1Y | 11.7% | 6.7% | 20.6% |
Return vs Industry: BIAF exceeded the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: BIAF underperformed the US Market which returned 20.5% over the past year.
Price Volatility
BIAF volatility | |
---|---|
BIAF Average Weekly Movement | 14.8% |
Biotechs Industry Average Movement | 10.4% |
Market Average Movement | 5.8% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BIAF's share price has been volatile over the past 3 months.
Volatility Over Time: BIAF's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 14 | Maria Zannes | www.bioaffinitytech.com |
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
bioAffinity Technologies, Inc. Fundamentals Summary
BIAF fundamental statistics | |
---|---|
Market cap | US$24.56m |
Earnings (TTM) | -US$8.37m |
Revenue (TTM) | US$4.94m |
4.7x
P/S Ratio-2.8x
P/E RatioIs BIAF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIAF income statement (TTM) | |
---|---|
Revenue | US$4.94m |
Cost of Revenue | US$3.31m |
Gross Profit | US$1.62m |
Other Expenses | US$9.99m |
Earnings | -US$8.37m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.72 |
Gross Margin | 32.88% |
Net Profit Margin | -169.42% |
Debt/Equity Ratio | 0.5% |
How did BIAF perform over the long term?
See historical performance and comparison